Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 21 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (10)
Early P 1 (1)
P 1 (2)
P 2 (1)
P 4 (1)

Trial Status

Unknown7
Completed5
Recruiting3
Withdrawn2
Not Yet Recruiting2
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT07498465Phase 1Withdrawn

A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia

NCT07221656Not Yet RecruitingPrimary

Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration

NCT07462299Not ApplicableNot Yet RecruitingPrimary

NUDT15/TPMT Multi-gene Guided 6-MP Dosing in Childhood ALL Maintenance Therapy

NCT06575296Phase 1Recruiting

Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

NCT07071051RecruitingPrimary

Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study

NCT06639958Not ApplicableSuspended

A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home

NCT04541056Not ApplicableActive Not Recruiting

Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae

NCT05452668Not ApplicableUnknown

Laser Therapy Effect on Oral Mucositis in Childhood Acute Lymphoblastic Leukemia Patients

NCT05729178RecruitingPrimary

Unravelling the Role of KCTD Protein Family in the Clinical Management of Childhood Acute Lymphoblastic Leukemias

NCT04723342Not ApplicableUnknownPrimary

Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot

NCT03981510Not ApplicableUnknown

Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation

NCT04626765Early Phase 1UnknownPrimary

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

NCT01953770Not ApplicableUnknownPrimary

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008

NCT03390387Not ApplicableUnknownPrimary

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

NCT01251575Phase 2Completed

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

NCT00537030Not ApplicableCompleted

Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

NCT00898079Completed

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

NCT00674193CompletedPrimary

Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

NCT01150669CompletedPrimary

Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia

NCT01990807Phase 4UnknownPrimary

Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia

Scroll to load more

Research Network

Activity Timeline